Eyepoint Pharmaceuticals, Inc. 8-K Filing

Ticker: EYPT · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1314102

Eyepoint Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyEyepoint Pharmaceuticals, Inc. (EYPT)
Form Type8-K
Filed DateOct 28, 2024
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Eyepoint Pharmaceuticals, Inc. (ticker: EYPT) to the SEC on Oct 28, 2024.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind).

How long is this filing?

Eyepoint Pharmaceuticals, Inc.'s 8-K filing is 2 pages with approximately 596 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-28 07:05:18

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On October 28, 2024, EyePoint Pharmaceuticals, Inc. (the "Company") posted an updated investor presentation (the "Presentation") on its website at www.eyepointpharma.com which included estimated cash and investments on hand as of September 30, 2024 and certain other corporate updates. The amounts included in the presentation were calculated prior to the completion of a review by the Company's independent registered public accounting firm and are therefore subject to change upon completion of the Company's quarterly report for the period ended September 30, 2024. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of September 30, 2024.

01 Other Events

Item 8.01 Other Events. On October 28, 2024, the Company issued a press release announcing positive interim data for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU as a six-month maintenance therapy for patients with diabetic macular edema ("DME"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. On October 28, 2024, the Company posted the Presentation on its website at www.eyepointpharma.com . A copy of the Presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc., dated October 28, 2024 99.2 Investor Presentation of EyePoint Pharmaceuticals, Inc. dated October 28, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: October 28, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.